Rapt Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Great, so we can get started now. I wanted to say thank you to Brian and Rodney, who are joining us here from the RAPT team.
Questions & Answers
And maybe we'll just kick it off with an overview. So if you could, just a brief overview of the company, particularly focused on what you see as key value drivers over the next 12 to 24 months.
Yes, sure. First of all, thanks, Corinne, for the invitation. Thanks to your group as well. So RAPT is a publicly traded company that focuses on oral small molecules that target key driver -- immunological drivers for both inflammation and cancer.
Through our own internal discovery, we have two lead assets, one is called RPT193. This is a once-daily oral that targets the same pathway as drugs such as dupilumab. But we think that the oral convenience would allow -- would be very attractive for patients with a broad
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |